Trial
NCT02668770
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Mologen AG
Condition
Advanced Cancers
Intervention
MGN1703
Why stopped
\<75% participation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-07